Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose rifampicin safety in complex drug-susceptible tuberculosis
2020-003146-36Phase 2Active
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rifampicin in drug-susceptible tuberculosis (DS-TB), pulmonary tuberculosis (TB) and extrapulmonary tuberculosis (EPTB), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Proportion of participants experiencing severe adverse events. Started Sep 2022; status: active.
02
Drugs
rifampicin
03
Conditions
drug-susceptible tuberculosis (DS-TB)pulmonary tuberculosis (TB)extrapulmonary tuberculosis (EPTB)
Beyond the preview
Go deeper on 2020-003146-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003146-36.